PRESS RELEASE
View printer-friendly version << Back
WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics Services
"In a rapidly changing and increasingly competitive global economy, the
ability to analyze large amounts of complex data to drive insight-based
decisions is critical to success. WNS has been a trusted partner in
delivering these high-value analytics solutions to GSK, and we are
delighted to announce this contract extension with a recognized leader
in the pharmaceutical industry,” said
WNS enables its global clients to make critical business decisions leveraging its research and analytics expertise, deep industry knowledge and robust delivery capabilities. WNS currently has over 2,000 research and analytics professionals supporting areas such as customer lifecycle analytics, market and business research, strategy and decision support, demand forecasting, customer risk scoring, loss management modeling, and measurement and reporting.
About WNS
Safe Harbor Statement
This
document includes information which may constitute forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, the accuracy of which are
necessarily subject to risks, uncertainties, and assumptions as to
future events. Factors that could cause actual results to differ
materially from those expressed or implied are discussed in our most
recent Form 20-F and other filings with the
Source:
WNS Global Services
Media Contact:
Sumi Gupta, Public
Relations
+91 (22) 4095 2263
sumi.gupta@wns.com
pr@wns.com
or
Investor
Contact:
David Mackey, Corporate SVP–Finance & Head of Investor
Relations
+1 201-942-6261
ir@wns.com